Atherosclerosis is a leading cause of cardiovascular diseases worldwide. Understanding its pathophysiology and exploring innovative treatment options like PCSK9 inhibitors are crucial for advancing cardiovascular health.
Atherosclerosis is a chronic condition characterized by the accumulation of fatty and fibrous materials within the innermost layer of the arteries, known as the intima. This process begins with the buildup of low-density lipoprotein cholesterol (LDL-C), which leads to the formation of atherosclerotic plaques. These plaques can become calcified and fibrous over time, narrowing the arterial lumen and restricting blood flow, potentially causing tissue ischemia.
Atherosclerosis is a major contributor to cardiovascular diseases (CVD), which include conditions such as myocardial infarction (heart attack), ischemic stroke, and peripheral artery disease. The pathogenesis of atherosclerosis involves